Additionally, MGMT immunoreactivity was evaluated in 23 silent subtype 3 adenomas; 78% showed no MGMT immunoreactivity, 17% displayed immunoreactivity in <25% of the tumor cells, and none of the tumors showed high immunoreactivity (>50%) (121). This evidence concerns the gene MGMT and neoplasm.